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The microbiota, intestinal and oral [1,2], have been the focus
of a growing number of papers, beneﬁting from the use of
the best molecular tools with meta-genomics approaches
allowing either the sequencing of the totality of sampled
genes taken from mucous membranes, in particular the faeces
including bacteria, viruses and Archaea, or the sequencing of
amplicon having ampliﬁed all the bacteria [3–6].
These papers represent the beginning of a new era that
will reconsider the human being as an ecosystem in a com-
plex environment modulated by age, food, antimicrobial
agents, pollutants and invasions of other microbes [7–12].
We are living in a period of rapid discoveries within which
available data should be carefully interpreted: each month,
new information is provided that often contradicts former
data [13–16]. Patience will be needed before stable assump-
tions are provided in this ﬁeld. Nevertheless the manipula-
tion of the microbiota, and in particular that of the
microbiota gut, is a story of more than 100 years going back
to Metchnikov’s works, and the manipulation of the digestive
microbiota of animals has been used in the farm industry for
more than 50 years through the use of probiotics or antibi-
otics for fattening farm animals [17]. Current work reveals
the need for a great scientiﬁc effort to be made in this ﬁeld,
if possible independent of the actors of the food industry, in
order to better understand the relationship between the
bacteria of the microbiota and their host and to avoid the
bias of publication that has recently been reported [18].
However, it should be acknowledged that the role of pro-
biotics in human health (based on an analysis of more than
11 000 references), in the long term, has not been estab-
lished and requires additional independent work [19].
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